Hematology · Triosephosphate Isomerase Deficiency

Managing Symptoms and Exploring Future Research

At a Glance

TPI deficiency has no cure or universally effective standard drug, so care is individualized and focuses on anemia, breathing, mobility, and movement symptoms. Treatments such as deep brain stimulation and experimental drugs or transplants require specialist review.

There is currently no cure for triosephosphate isomerase (TPI) deficiency, and no “standard” drug treatment exists that works for every patient ^[1]. Because this condition is ultra-rare, medical care focuses on supportive management—treating symptoms as they appear to improve comfort, mobility, and overall health ^[2]^[3].

Standard Symptomatic Care

Your care team will likely include several specialists working together to manage the different ways TPI deficiency affects the body.

Hematology and Transfusions

Managing chronic hemolytic anemia is a priority. A hematologist will track blood counts and may recommend blood transfusions based on symptoms rather than a single threshold. If repeated transfusions are needed, monitoring for iron overload (often using ferritin tests) is necessary, and chelation therapy may be required to protect organs ^[4]. Do not start supplements like iron without instruction from the care team.

Respiratory and Immune Support

Individuals with TPI deficiency are more susceptible to respiratory infections and may develop weakness in the muscles used for breathing ^[2]^[5].

Monitoring: Regular check-ups with a pulmonologist help monitor breathing strength.
Intervention: Some may eventually require non-invasive ventilation (like a CPAP or BiPAP machine) or specialized airway clearance techniques to help breathe and clear mucus during illnesses ^[5]^[6].

Mobility and Orthopedic Care

Progressive muscle weakness or stiffness often makes moving difficult.

Physical and Occupational Therapy: These are essential for maintaining joint flexibility and finding ways to perform daily tasks ^[5]. Swallowing assessments are also vital.
Aided Mobility: The team may recommend orthotics (braces), walkers, or specialized wheelchairs to help stay mobile and engaged ^[5].
Orthopedic Surgery: In some cases, surgery may be needed to correct bone or joint issues caused by long-term muscle imbalances ^[7].

Deep Brain Stimulation (DBS)

For those whose primary symptom is severe dystonia (involuntary muscle twisting), a procedure called Deep Brain Stimulation (DBS) may be an option. This involves placing small electrodes in a part of the brain called the globus pallidus internus (GPi) to help regulate muscle movements ^[7].

Evidence: In a small study of siblings with a specific type of TPI deficiency, DBS led to “meaningful improvement” in their ability to walk and maintain their posture ^[7]. It is not a cure and is only used for certain types of movement problems.

Investigational and Off-Label Treatments

You may encounter information about experimental treatments. It is vital to understand that these are not yet standard care and often have very limited data in humans.

Protein Stabilization (PHD Inhibitors)

Researchers are testing a class of drugs called PHD inhibitors (such as vadadustat). These drugs are typically used for kidney-related anemia, but they may help “stabilize” the shaky TPI protein inside cells ^[8].

Status: This is highly experimental. One patient treated with vadadustat showed improvements in hand coordination and muscle control ^[8]. However, this is a single-patient report, not an established safety or efficacy profile, and carries known drug-specific risks.

Bone Marrow Transplantation (BMT)

Because TPI deficiency affects red blood cells, some have considered bone marrow transplantation (replacing the blood-forming cells with healthy donor cells).

Status: While BMT has successfully “cured” the blood-related symptoms in mice, it has only been performed in a very small number of human patients ^[9]^[1]. Importantly, BMT does not correct the disease in the brain and nerves, and carries major risks such as severe infection, graft-versus-host disease, and mortality.

Dietary Approaches

You may read about the ketogenic diet or specialized oils like triheptanoin.

Status: These have shown some benefit in improving seizures and energy in TPI-deficient fruit flies (Drosophila), but there is no evidence yet that they work or are safe for humans with this condition ^[1]. They are not considered a standard treatment at this time.

Managing TPI deficiency requires a cautious, individualized approach. Always discuss any new treatment or supplement with the specialist before starting.

Common questions in this guide

Is there a cure or standard medicine for TPI deficiency?

There is currently no cure and no single standard drug that works for every person with TPI deficiency. Care is individualized and usually focuses on managing anemia, breathing, movement, mobility, and other symptoms.

How are transfusions and iron overload managed in TPI deficiency?

A hematologist may recommend transfusions based on symptoms and blood counts rather than one fixed number. If transfusions are repeated, the care team can monitor for iron overload, often with ferritin testing, and use iron-chelation treatment when needed; iron supplements should not be started without medical advice.

What can help with breathing problems and respiratory infections?

People with TPI deficiency may be more vulnerable to respiratory infections and weakness in the muscles used for breathing. A pulmonologist can monitor breathing, and some people may benefit from non-invasive ventilation such as CPAP or BiPAP and airway-clearance techniques during illness.

Can deep brain stimulation help severe dystonia in TPI deficiency?

Deep brain stimulation may be considered for selected people whose main problem is severe dystonia, or involuntary muscle twisting. It places electrodes in a movement-related brain region and may improve walking or posture in some patients, but it is not a cure and evidence is limited.

Is vadadustat a proven treatment for TPI deficiency?

Vadadustat is an experimental drug being studied because it may help stabilize the TPI protein inside cells. Reports of benefit are limited to a single patient, so its safety and effectiveness for TPI deficiency are not established and its drug-specific risks must be considered.

Does bone marrow transplantation cure TPI deficiency?

Bone marrow transplantation has improved blood-related disease features in mice and has been used in only a very small number of people. It does not correct effects in the brain and nerves and carries serious risks, including severe infection, graft-versus-host disease, and death.

How can we find clinical trials or expanded-access options for TPI deficiency?

Because TPI deficiency is ultra-rare, clinical trial and expanded-access opportunities may be limited and eligibility can vary. Ask a specialist familiar with rare metabolic or neuromuscular disorders to review current options and explain the evidence, risks, and monitoring involved.

Get notified when new evidence is published on Triose phosphate-isomerase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (9)

1
TPI deficiency: A case report and review of the literature.
Williams A, Weisz-Hubshman M, Rossi V, et al.
Molecular genetics and metabolism 2025; (146(1-2)):109227 doi:10.1016/j.ymgme.2025.109227.
PMID: 40897044
2
Challenges in the Diagnosis and Management of Triosephosphate Isomerase Deficiency: A Case Report.
Ramos C, Pereira I, Coelho J, et al.
Reports (MDPI) 2025; (8(3)) doi:10.3390/reports8030162.
PMID: 40981120
3
Experiences of caregivers of children with inherited metabolic diseases: a qualitative study.
Siddiq S, Wilson BJ, Graham ID, et al.
Orphanet journal of rare diseases 2016; (11(1)):168 doi:10.1186/s13023-016-0548-2.
PMID: 27927250
4
Diagnosis and clinical management of enzymopathies.
Luzzatto L
Hematology. American Society of Hematology. Education Program 2021; (2021(1)):341-352 doi:10.1182/hematology.2021000266.
PMID: 34889365
5
A High-Content Screening Assay for Small Molecules That Stabilize Mutant Triose Phosphate Isomerase (TPI) as Treatments for TPI Deficiency.
Vogt A, Eicher SL, Myers TD, et al.
SLAS discovery : advancing life sciences R & D 2021; (26(8)):1029-1039 doi:10.1177/24725552211018198.
PMID: 34167376
6
Triosephosphate Isomerase Deficiency: E105D Mutation in Unrelated Patients and Review of the Literature.
Selamioğlu A, Karaca M, Balcı MC, et al.
Molecular syndromology 2023; (14(3)):231-238 doi:10.1159/000528192.
PMID: 37323194
7
Familial Dystonia Due to Homozygous TPI1 c.718G>A (p.Glu240Lys): A Three-Sibling Case Series Including Two Treated with Deep Brain Stimulation of the Globus Pallidus Internus.
Yavuz Z, Önder H, Munis ÖB, Çomoğlu SS
Annals of Indian Academy of Neurology 2026; (29(1)):87-90 doi:10.4103/aian.aian_882_25.
PMID: 41692693
8
PHD Inhibitor Vadadustat: The First Drug Therapy for Triosephosphate Isomerase Deficiency.
Scalais E, Patel P, Satterfield S, et al.
Genes 2026; (17(10)) doi:10.3390/genes17101192.
PMID: 42938308
9
Bone marrow transplantation corrects haemolytic anaemia in a novel ENU mutagenesis mouse model of TPI deficiency.
Conway AJ, Brown FC, Hortle EJ, et al.
Disease models & mechanisms 2018; (11(5)) doi:10.1242/dmm.034678.
PMID: 29720471

This page describes supportive and investigational approaches for TPI deficiency for educational purposes only. It is not medical advice; discuss treatments, supplements, and clinical trials with your hematology, neurology, pulmonology, or other specialist.